Full-Time
Asimov
51-200 employees
Provides genetic design solutions for biopharma
No salary listed
Senior
Boston, MA, USA
This position is hybrid, indicating that some in-office days are required.
- Bachelor’s degree in Life Sciences, Business, or a related field; advanced degree preferred.
- 5+ years of experience in account management, client success, or customer-facing roles within biotech, life sciences, or CDMO/CRO services.
- Proven track record of managing complex client relationships and delivering exceptional customer experiences.
- Strong commercial and operational acumen with experience in technical project coordination.
- Excellent interpersonal and communication skills, with the ability to engage senior stakeholders.
- Analytical mindset with the ability to assess account performance and provide strategic recommendations.
- Serve as a primary point of contact for clients, building trust and fostering long-term partnerships.
- Collaborate closely with the operations team to ensure the successful delivery of projects, meeting or exceeding client expectations.
- Act as the customer advocate and the eyes of Asimov for gaining industry-specific understanding with a commercial perspective in mind.
- Serve as a facilitator for engagements between Asimov and third-party value chain partners (CDMO, CRO, etc), ensuring alignment with customer preferences.
- Identify upselling and cross-selling opportunities within existing accounts to maximize customer lifetime value.
- Regularly report on account performance, including metrics on revenue contribution, client satisfaction, and project delivery.
- Familiarity with synthetic biology, cell line development, or upstream process development is a plus.
- Proficiency in CRM tools and project management software is preferred.
Asimov operates in the synthetic biology field, providing a combination of engineered cells, genes, and software to assist in advanced genetic design. Their main products include cloud-based software that helps clients in the biopharmaceutical industry design, simulate, and optimize genetic systems, along with engineered GMP host cells for therapeutic uses. Asimov stands out from competitors by offering a unique guarantee on their high titer cell lines for monoclonal antibodies, promising '4 g/L or it's free,' which reduces risk for their clients. The company's goal is to enable biopharma companies to efficiently produce protein therapeutics and scalable viral vectors, ensuring high quality and performance through their specialized teams in synthetic biology and process development.
Company Size
51-200
Company Stage
Series B
Total Funding
$204.7M
Headquarters
Boston, Massachusetts
Founded
2017
Simplify's Take
What believers are saying
- Stable cell line development reduces costs and increases scalability in lentiviral production.
- Acquisition of The Foundry enhances Asimov's expertise in genetic design and engineering.
- Growing biotech investments indicate a robust market for Asimov's engineered cell lines.
What critics are saying
- Competition from LatchBio's code-free biocomputing infrastructure challenges Asimov's software offerings.
- Integration of The Foundry may lead to potential cultural clashes and operational disruptions.
- Rapid data generation in synthetic biology may strain Asimov's data processing capabilities.
What makes Asimov unique
- Asimov offers a '4 g/L or it's free' promise for monoclonal antibodies.
- The LV Edge Producer System eliminates GMP plasmid costs and reduces process complexity.
- Asimov integrates synthetic biology, computer-aided design, and machine learning for genetic design.
Help us improve and share your feedback! Did you find this helpful?
Growth & Insights and Company News
6 month growth
↑ 2%1 year growth
↑ 3%2 year growth
↑ 9%BOSTON--(BUSINESS WIRE)--Asimov, the synthetic biology company advancing the design and manufacture of therapeutics, today announced the expansion of its LV Edge System with the launch of a fully stable cell line development service. There are now two ways for customers to access Asimov’s cell line technology to minimize cost and manufacturing risk, depending on their needs:The LV Edge Packaging System, launched earlier this year, which enables a single plasmid transfection that achieves E8 TU/mL.The new, fully-stable LV Edge Producer cell line development service, which generates clones that achieve E9 TU/mL with no transient transfection required.The LV Edge Producer System completely eliminates GMP plasmid cost and greatly reduces process complexity and variability by stably integrating all the genes for lentiviral production into the host cell. Current processes for lentiviral production are inherently scale-limited and variable due to the need for multi-plasmid transient transfection. Furthermore, the reliance on GMP plasmids and transfection reagents substantially increases costs and introduces supply chain and product variability risks. The development of a fully stable cell line technology enables scalable, reproducible and low-cost production of lentivirus, which will unlock applications for larger therapeutic indications
The Foundry, formerly of MIT and the Broad Institute, has joined Asimov; its team, leadership, and infrastructure have moved to Asimov's Boston headquarters.headquarters. The group has nucleated Asimov Labs, a new R&D center for advanced genetic design.BOSTON, Aug. 2, 2023 /PRNewswire/ -- Asimov, the synthetic biology company building tools to design living systems, announced today that The Foundry, previously of MIT and the Broad Institute, has joined its ranks. The Foundry was established by Professor Christopher Voigt (MIT) in 2012 as part of DARPA's Living Foundries program to expand the limits of genetic design. During its tenure, the Foundry developed novel engineering techniques and used them to produce thousands of molecules, materials, genetic circuits, and sensors. In its new home at Asimov, the team will continue to pioneer genetic design as Asimov Labs, a center dedicated to developing technologies to open new frontiers for biological engineering.The Foundry, formerly of MIT and the Broad Institute, has joined AsimovAsimov develops cellular, genetic, and computational tools to enable next-generation therapeutics
LatchBio founders: Alfredo Andere, Kenny Workman, and Kyle Giffin. LatchBioMost industries today are experiencing an unprecedented data deluge – and synthetic biology is no exception. Twenty years ago, a typical biological experiment generated 3-5 megabytes of information. Today, a routine synthetic biology workflow produces anywhere from 1,000 to 40,000 terabytes. That is a billion times more data! Such a large number of data points is simply impossible to interpret by human eye. This is why almost every bio lab today has to set up custom bioinformatics pipelines, invest in cloud computing, and master advanced data visualization software – all that just to see the results of their experiments.A San Francisco startup, LatchBio, hopes to make data analysis much easier for biologists with its full-stack biocomputing infrastructure
Image/Anastasiia SlynkoThe companies Apogee Therapeutics, Pulmocide and Qitan Technology bagged the biggest biotech investments in December 2022. Around the world, immunology and manufacturing players attracted the biggest funding rounds.We’ve hit 2023 and a lot of biotech fundraising took place in the final month of 2022. We’ve gathered the biggest biotech investments that went to private companies around the world and split them into healthcare and industrial biotechnology-focused verticals.Healthcare investmentsThe U.S.’ top private biotech healthcare investment went to Apogee Therapeutics. The Paragon Therapeutics spinout took home $149 million in a Series B round to fund the development of drugs for a range of undisclosed immunological and inflammatory conditions.An honorable mention goes to Alpha9 Theranostics based in the U.S.’s neighbor, Canada. The firm raised $75 million in a bid to develop radiopharmaceutical treatments for cancer.The top European biotech healthcare investment round went to Pulmocide in the U.K. The firm’s $52 million Series C round will be used to finance the development of inhaled drugs treating viral and fungal infections in the respiratory tract.Content continues below Related ContentThe Chinese firm MaxVax topped the healthcare biotech investment list in Asia-Pacific with a $43 million investment in December 2022
“Before COVID, if I said we need to reproduce or scale, people would ask, why?” says Doug Densmore, Co-Founder of Lattice Automation and Asimov. “Now, people get it.” The consequence? An automated revolution in biotechnology, where cheap computing meets mass-reproducible synthetic biology, begetting an industry with the potential to surpass anything that went before it. The opportunity is […]